About SeQure Dx
SeQure Dx is a company based in Waltham (United States) founded in 2020 by Ellen Sheets was acquired by MaxCyte in January 2025. SeQure Dx has raised $22.29 million across 3 funding rounds from investors including MaxCyte, ARE and RiverVest Venture Partners. SeQure Dx offers products and services including ONE-seq, SAFER Detection, Guide Profiler, Electroporation Systems, and ATx System. SeQure Dx operates in a competitive market with competitors including Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
- Headquarter Waltham, United States
- Founders Ellen Sheets
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of SeQure Dx
SeQure Dx offers a comprehensive portfolio of products and services, including ONE-seq, SAFER Detection, Guide Profiler, Electroporation Systems, and ATx System.
Variant-aware guide selection for therapeutic gene editing.
Efficient interrogation of DNA rearrangements in edited cells.
Computational aid for improved guide RNA selection in CRISPR.
Systems for cell transfection in therapy production.
Device for small to medium static electroporation processes.
Scalable electroporation for up to 20 billion cells.
Clinically validated flow-through electroporation device.
Tool for gram-scale protein production via electroporation.
People of SeQure Dx
Unlock access to complete
Sales and Marketing
2 people
Software Development Team
1 people
Leadership Team
1 people
Senior Team
1 people
Unlock access to complete
Funding Insights of SeQure Dx
SeQure Dx has successfully raised a total of $22.29M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $2.18 million completed in November 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in SeQure Dx
SeQure Dx has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include MaxCyte, ARE and RiverVest Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Digitalis Ventures is engaged in health-focused investments.
|
Locked | Locked | Locked |
Investor details for SeQure Dx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by SeQure Dx
Investment portfolio details for SeQure Dx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - SeQure Dx
Detailed financials for SeQure Dx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sequre Dx Comparisons
Peer comparison for SeQure Dx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of SeQure Dx
SeQure Dx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
|
| Locked | Locked | Locked |
Diagnostic services are provided through laboratories and radiology units.
|
Detailed competitors of SeQure Dx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sequre Dx
Complete news archive for SeQure Dx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SeQure Dx
SeQure Dx was founded in 2020 and raised its 1st funding round 1 year after it was founded.
SeQure Dx is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
SeQure Dx is a funded company, having raised a total of $22.29M across 3 funding rounds to date.
Developer of personalized diagnostics for gene-editing therapies. The companys technologies GUIDE-seq and ONE-seq enable the identification and confirmation of target sites for developing gene therapies.
SeQure Dx's top competitors include Juno Therapeutics, Poseida Therapeutics and Denali Therapeutics.
SeQure Dx offers ONE-seq, SAFER Detection, Guide Profiler, Electroporation Systems, and 4 more products and services.
SeQure Dx has 8 investors. Key investors include MaxCyte, ARE, RiverVest Venture Partners, Mass General Brigham Ventures, and Digitalis Ventures.